Ocrevus Ocrelizumab Injection

1. Indications and Usage
Multiple Sclerosis: Indicated for the treatment of adult patients with clinically isolated syndrome, relapsing forms of multiple sclerosis (MS), or primary progressive MS.
2. Dosage and Administration
Standard Dosing: The recommended dose is 600 mg administered intravenously.
Administration Schedule: The initial course consists of two 600 mg infusions separated by 14 days. Subsequent maintenance therapy involves one 600 mg infusion every 6 months.
Infusion Precautions: Infusions should be administered at a rate of no more than 100 mg/hour. Premedication with antihistamines and acetaminophen is recommended prior to each infusion.
3. Mechanism of Action
CD20 Targeting: Ocrelizumab is a recombinant humanized monoclonal antibody that selectively binds with high affinity to the CD20 antigen.
B-Cell Depletion: The CD20 antigen is expressed on the surface of pre-B and mature B lymphocytes but not on plasma cells or normal stem cells.
Immune Suppression: Binding to CD20 depletes B cells through mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby reducing the autoimmune attack on the central nervous system in MS.
4. Safety and Warnings
Infusion-Related Reactions: These are the most common adverse reactions and can include pruritus, rash, urticaria, angioedema, pyrexia, and hypotension.
Serious Infections: Patients are at increased risk for infections, including upper respiratory tract infections and urinary tract infections.
Hepatitis B Reactivation: Reactivation of Hepatitis B virus has been reported in patients treated with B-cell depleting therapies.
Progressive Multifocal Leukoencephalopathy (PML): PML, a rare opportunistic viral infection of the brain, has been reported.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include nasopharyngitis, respiratory tract infection, pyrexia, and nausea.
Clinical Research: Clinical trials have demonstrated that ocrelizumab significantly reduces the annualized relapse rate and delays disability progression in relapsing and primary progressive MS compared to placebo.
6. Drug Interactions
Live Vaccines: Live or attenuated vaccines should not be administered during treatment.
Immunosuppressants: Concomitant use with other immunosuppressive agents may increase the risk of infection.
Antihypertensives: Antihypertensive medications should be considered for temporary discontinuation before and during infusion to reduce the risk of hypotension.
7. Pharmaceutical Information
Composition: The active ingredient is ocrelizumab, a recombinant DNA-derived monoclonal antibody.
Appearance: It is a clear to slightly opalescent, colorless to pale yellow liquid.
Storage: Store at 2°C to 8°C in the original carton to protect from light. Do not freeze or shake.